Wegovy-maker Novo Nordisk partners with OpenAI to fasten drug development
This image was generated by AI and may not depict real events.
Danish drugmaker Novo Nordisk has partnered with OpenAI to use artificial intelligence in its business, from drug discovery to manufacturing. The partnership aims to improve efficiency and help Novo regain ground in the weight-loss drug market.
Novo Nordisk, the maker of Wegovy and Ozempic, has partnered with OpenAI. The partnership will use OpenAI's technology to analyze complex datasets and improve efficiency in manufacturing and operations. Novo is seeking to regain ground in the obesity-drug market. The company will start pilot programs across research and development, manufacturing, and commercial operations. Full integration is planned by the end of 2026. OpenAI will also help train Novo's global workforce, increasing AI literacy and productivity.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.